Virtual Library
Start Your Search
M. Shimomura
Author of
-
+
P2.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 210)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.02-010 - Pathological Examination of Primary Lung Adenocarcinoma Cases That Were Positive for Intraoperative Pleural Effusion (E1(+), M1a) (ID 1634)
09:30 - 09:30 | Author(s): M. Shimomura
- Abstract
Background:
Malignant pleural effusion or dissemination is not an indication for surgery or poor prognosis. However, cases that are positive for intraoperative pleural effusion may have better prognosis. We retrospectively examined cases that were positive for intraoperative pleural effusion.
Methods:
We retrospectively investigated the data of 96 patients with primary lung adenocarcinoma who underwent surgery between 2010 and 2013 at the Department of Thoracic Surgery of the Ayabe City Hospital. A total of 11 patients (11.5%) were positive for intraoperative pleural effusion. We compared the data between these patients and the patients who were negative for intraoperative pleural effusion.
Results:
The mean patient age was 72 years (range, 57–83 years); 4 patients were men and 7 were women. The median time from diagnosis to surgery was 89 days (range, 39–1610 days). The median tumor size was 42 mm (range, 15–90 mm). All cases were clinical N0 tumors. Regarding the surgical technique, 2 patients underwent exploratory thoracotomy, 4 underwent wedge resection, and 5 underwent lobectomy. The following pathological findings were obtained. Pleural invasion was pl1 in 1 patient, pl2 in 6, and pl3 in 2. Five patients showed lymphatic vessel invasion (Ly+), 4 patients showed vascular invasion (V+), and 3 patients showed the presence of micropapillary patterns (MPPs). One patient was positive for an EGFR mutation. Five patients had received adjuvant chemotherapy. The overall 4-year survival rate was 72.7%. The patients with E(+) showed a significantly higher extent of Ly+, pleural invasion (pl2), and MPPs (P < 0.05 for all).
Conclusion:
Primary lung adenocarcinoma with intraoperative findings of malignant pleural effusion tend to show Ly+, vascular invasion, and MPPs.
-
+
P3.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 214)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.03-004 - Clinicopathological Factors Associated With Postoperative Survival in Patients With Pathological Stage IB Non-Small-Cell Lung Cancer (ID 1400)
09:30 - 09:30 | Author(s): M. Shimomura
- Abstract
Background:
The treatment outcomes of patients with non-small-cell lung cancer have improved because of advances in diagnostic imaging and multidisciplinary therapies. However, the reported 5-year survival rate of patients with pathological stage IB non-small-cell lung cancer is approximately only 60%. We evaluated the clinicopathological factors associated with postoperative survival in patients with pathological stage IB non-small-cell lung cancer.
Methods:
From July 2006 through July 2014, 56 patients with pathological stage IB non-small-cell lung cancer underwent lung resection. We retrospectively evaluated the factors of age, sex, preoperative carcinoembryonic antigen level, pathological classification, tumor diameter, EGFR mutation, and pleural, lymph duct, and venous invasion.
Results:
The 5-year survival rates of the overall cohort and of patient subsets with squamous and non-squamous cell carcinoma were 60.8%, 22.7%, and 83.2%, respectively. A survival analysis revealed that both squamous cell carcinoma and v1 venous invasion were associated with poor prognosis. Further analysis revealed that the 5-year survival rates of patients with v1 and v0 invasion were 24.6% and 73.9%, respectively.
Conclusion:
Patients with pathological stage IB non-small-cell lung cancer classified as squamous cell carcinoma and those with v1 invasion have a higher risk of recurrence.
